NOUS-209 is under clinical development by Nouscom and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NOUS-209’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NOUS-209 overview

NOUS-209 is under development for the treatment of solid tumors incuding gastric cancer, colorectal cancer and gastroesophageal junction microsatellite instable cancers. The therapeutic candidate is developed based on Exovax platform which comprises of human great apes adenovirus (GAd) and modified vaccinia virus ankara (MVA) viral vectors encoding cancer neoantigens.

Nouscom overview

Nouscom is a immunotherapy company. It develops a genetic neoantigen vaccine and oncolytic viruses for prevention and treatment of cancer. Nouscom is headquartered in Basel, Switzerland.

For a complete picture of NOUS-209’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.